BioRestorative Therapies, Inc. Operating Income Loss

• BioRestorative Therapies, Inc. showed a decrease of -35.4% in Operating Income Loss from 2024 to 2025.
• This data is from BioRestorative Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2010 to 2025), BioRestorative Therapies, Inc.'s Operating Income Loss has declined by 656.1%.
• Historical annual values: Fiscal year 2025: -$15.65 million | Fiscal year 2024: -$11.56 million | Fiscal year 2023: -$15.22 million | Fiscal year 2022: -$18.97 million | Fiscal year 2021: -$26.31 million | Fiscal year 2020: -$2.75 million | Fiscal year 2019: -$8.43 million | Fiscal year 2018: -$7.65 million | Fiscal year 2017: -$8.37 million | Fiscal year 2016: -$7.79 million | Fiscal year 2015: -$7.17 million | Fiscal year 2014: -$4.92 million | Fiscal year 2013: -$4.75 million | Fiscal year 2012: -$5.57 million | Fiscal year 2011: -$3.55 million | Fiscal year 2010: -$2.07 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026